Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.

Markolf HanefeldJuan M ArteagaLawrence Alan LeiterGiulio MarchesiniElena NikonovaMarina ShestakovaWilliam StagerRicardo Gómez-Huelgas

Published in: Diabetes, obesity & metabolism (2017)

This study demonstrates that baseline renal status does not affect efficacy outcomes in lixisenatide- vs placebo-treated patients, and that no lixisenatide dose adjustment is required for patients with T2D with mild or moderate renal impairment.

Keyphrases

newly diagnosed
ejection fraction
prognostic factors
high intensity
randomized controlled trial
clinical trial
patient reported outcomes
metabolic syndrome
adipose tissue
study protocol